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Introduction: Tendinitis affects a substantial number of people in several occupations involving 
repetitive work or direct trauma. Iontophoresis is a therapeutic alternative used in the treatment 
of injury during the inflammatory phase. In recent years, gold nanoparticles (GNP) have been 
studied due to their therapeutic anti-inflammatory capacity and as an alternative to the transport 
of several proteins. 
Purpose: This study evaluates the therapeutic effects of iontophoresis using GNPs and diclofenac 
diethylammonium on inflammatory parameters in rats challenged with traumatic tendinitis.
Methods: Wistar rats were divided in three treatment groups (n = 15): (1) iontophoresis + 
diclofenac diethylammonium; (2) iontophoresis + GNP; and (3) iontophoresis + diclofenac 
diethylammonium + GNP. External control was formed by challenged tendons without treatment 
(n = 15). Iontophoresis was administered using 0.3 mA direct current on 1.5 cm² electrodes. 
Results: The levels of both inflammatory cytokines were significantly higher in untreated 
challenged rats, when compared with the control (5.398 ± 234 for interleukin 1 beta and 6.411 ± 432 
for tumor necrosis factor alpha), which confirms the occurrence of an inflammatory stage in injury 
(P  0.05). A significant decrease was observed in expression of cytokines interleukin 1 beta in the 
three treatment groups, in comparison with untreated challenged tendons, although, in the group 
treated with diclofenac and GNP, results were similar to the control (1.732 ± 239) (P  0.05). 
Concerning tumor necrosis factor alpha, only the group treated with the association diclofenac 
and GNPs presented decreased levels, compared with the control (3.221 ± 369) (P  0.05). 
Conclusion: The results show the efficacy of drug administration using direct current to treat 
tendinitis in an animal model, and the potential anti-inflammatory, carrier, and enhancing effects 
of GNPs in iontophoresis.
Keywords: tendinous injury, proinflammatory cytokines, electrophoresis, iontophoresis, 
nanoparticles
Introduction
Tendons are specialized tissues that connect muscles to bones and transmit the motion 
generated by the former to the latter, producing joint movements. Apart from this, ten-
dons are living tissues that respond to mechanical effort as changes in metabolism, as 
well as in structural and mechanical properties.1 Tendinitis is a painful condition that 
takes place as a response to repetitive use or direct trauma. A short inflammation phase 
has been proved to take place in tendons challenged with overuse. In chronic cases, that 
is, in painful conditions brought about by tendon overuse, the therapeutic approaches 
commonly adopted with a view to modulating this inflammatory response have enjoyed International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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limited success. More recently, the term “tendinopathy” has 
been increasingly used to describe the variety of painful 
conditions resulting from overuse.2 Tendinopathy has not 
been studied in depth and, although a variety of medicinal 
drugs have been developed to treat the condition, there is little 
evidence to support the use of these substances with that end. 
One of the reasons behind the scarcity of effective treatments 
of tendinopathy lies in the meager body of knowledge gained 
in terms of its pathogenesis.3
Two proinflammatory cytokines expressed in tendinopa-
thies are interleukin 1 beta (IL-1β) and tumor necrosis factor 
alpha (TNF-α). TNF-α is the prototypical inflammatory 
cytokine that initiates the signaling cascade of other cyto-
kines and trophic factors. It may be released by different cell 
types and it exerts its effects by interacting with the respec-
tive receptor.3 A recent study demonstrated that TNF-α is 
distributed and expressed in tendinocytes in an inflammatory 
scenario, and that these cells undergo high apoptosis and 
proliferation rates in tendon inflammation. Both TNF-α and 
IL-1β act directly in the ascending pain pathways in an inflam-
matory process, being able to increase expression of nerve 
growth factor, cyclooxygenase 2, and nitric oxide synthase, 
apart from stimulating synaptic vesicle budding of the dorsal 
root ganglion, switching synaptic plasticity to the facilitation 
mode. IL-1β is possibly involved in the inhibition of the ability 
of glial cells to remove glutamate molecules from the syn-
aptic cleft, adding to neuronal excitability of tumor necrosis 
factor receptor 1.4 A significant increase in the expression of 
these inflammatory cytokines in tendinitis leads to fibroplast 
proliferation and therefore to tendon degeneration.5
Iontophoresis has been studied for over a century due to its 
ability to release medicinal drugs through the transcutaneous 
pathway based on low-frequency electrical currents.5,6 In spite 
of increasing skin permeability, iontophoresis promotes the 
transport of electrical charges through the corneous extract. 
Strongly charged drugs are transported via electrophoresis, 
while weakly charged or electrically neutral drugs may be 
transported by the electroosmotic flux of water generated by 
the preferential movement of mobile cations, like Na+, for 
instance, instead of the fixed anions in the corneous extract.7
The drugs commonly administered through the 
transcutaneous pathway are released though a variety 
of mechanisms, with specific markers. In rehabilitation 
approaches, however, drug release markers through the 
transcutaneous pathway are basically local; the three most 
common families of drugs used are: (1) anesthetics; (2) 
anti-irritation agents; and (3) anti-inflammatory drugs, like 
steroidal or   nonsteroidal drugs.8
According to Santi and Singh,9 two mechanisms are 
responsible for the physiological effect of iontophoresis: 
“  ionophoresis,” where ions are repelled by an electrode with 
identical charge, and “electroosmosis,” defined as the local 
movement of fluids through skin pores. A few controlled 
studies have appropriately addressed the therapeutic use of 
iontophoresis. Nino et al10 and Grewal et al11 reported the pos-
sibility that large molecules are transported by iontophoresis. 
Molecular structure is the key element in iontophoretic 
transport. Apart from this, the sequence of chemical groups 
in the molecular structure is also important.
In recent years, nanomaterials, whose dimensions lie in 
the 1–100 nm range, have been used in the development of 
unique devices that afford new functional properties from 
the chemical and physical standpoint. The potential of nano-
particles concerning chromatographic and electrophoretic 
techniques has been investigated in more detail of late.12 
Nanotransporters represent a new platform for the transport 
of therapeutic agents to specific targets. More specifically, 
gold nanoparticles (GNPs) have become the object of 
special interest due to their optical, electronic, redox, and 
catalytic properties,12 and are today seen as an attractive 
alternative concerning the transport of several proteins 
and their respective markers, small drug molecules, large 
biomolecules, DNA, or RNA. Today it is known that the 
efficient release of these therapeutic agents is a condition 
for therapy success.13
Apart from being inert and nontoxic, GNPs are easy to 
prepare and stable in solution in the long term.14 Also, GNPs 
may be prepared in varied sizes and shapes.13 GNPs are able 
to release large molecules, not only small-molecule medici-
nal drugs. Tsai et al15 evaluated the intra-articular release of 
GNPs in induced arthritis in a rat model and observed that the 
technique inhibited cell proliferation and migration, reduc-
ing histological scores, microcapillary density, macrophage 
density, and TNF-α and IL-1β levels. Another study assessed 
the anti-inflammatory effects of GNPs between 20 and 45 nm 
in diameter on focal brain injury. The results demonstrated 
that treatment reduced brain levels of TNF-α, oxidative stress 
to DNA, and postapoptosis markers.16 Also, Turkevich et al17 
investigated the antiangiogenic properties of GNPs using 
an ovary tumor model, observing that nanogold selectively 
inhibited induced expression of human vascular endothelial 
growth factor in human umbilical vein endothelial cells and 
the induced proliferation of the basic fibroblast growth   factor, 
respectively.
In light of these anti-inflammatory properties of GNPs, 
as well as their ability to bind to reactive molecules in International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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drug delivery systems, the present study investigates the 
potential applications of GNPs as a drug delivery technique 
to shed more light on the inflammatory mechanism behind 
  tendinopathy. The results may be useful in the development 
of new treatment approaches using GNPs, iontophoresis, and 
medicinal drugs. The present study tests the hypothesis that 
GNP used in iontophoresis increases drug potency, promoting 
the ideal anti-inflammatory therapeutic effect in Achilles 
tendinitis challenge in rats.
Materials and methods
Preparation of gNPs
GNPs were prepared as described by Turkevich et al.17 All 
chemicals used were of the highest analytical grade and pur-
chased from Sigma Aldrich (St Louis, MO). All glass vials 
were washed in aqua regia and rinsed in ultrapure water, after 
which 50 mL aurochloric acid 2 mM were gently warmed 
up to 90°C, whereupon 5 mL sodium citrate 39 mM were 
added. Then, the reaction medium was refluxed under intense 
shaking for 20 minutes, left to cool at room temperature 
before being centrifuged at 7000 rpm for 30 minutes. After 
centrifugation, the GNPs present in the supernatant were 
collected.
Animals
In total, 60 male Wistar rats (250 and 300 g) were used. 
Animals were obtained from the animal center maintained by 
the authors’ university (Universidade do Extremo Sul Catar-
inense, Criciúma, Santa Catarina, Brazil) and transported 
in cages containing five animals each to the laboratory. 
Animals were kept under 12-hour dark:light cycles and fed 
on commercial food, with water ad   libitum. Next, rats were 
randomly divided into three treatment groups of injury 
challenged tendons (n = 15): (1)   iontophoresis + diclofenac 
diethylammonium, (2)   iontophoresis + GNP gel, and (3) with 
  iontophoresis + diclofenac diethylammonium + GNP gel. 
An external control formed by challenged tendons without 
treatment was included (n = 15). For intragroup comparison, 
the uninjured contralateral tendons of the respective treat-
ment group were used as internal controls. All procedures 
involving animals were carried out in accordance with an 
experimental protocol approved by the Ethics Commis-
sion for Animal Use, UNESC, following the Principles of 
Animal Care.18
Tendinous injury model
The injury model was adapted for tendinous injury based on 
Rizzi et al19 for muscle injury. An intraperitoneal injection 
of ketamine purchased from Bayer (São Paulo, Brazil) and 
xylazine obtained from Fort Dodge (Fort Dodge, IA) (80 and 
20 mg/kg, respectively) was used to anesthetize rats. Next, 
rats were challenged with one single impact by direct trauma 
on Achilles tendon using an injury press, EQ-179, developed 
by the Industrial Center of Teaching and Research Equipment 
(CIDEPE, Rio Grande do Sul, Brazil). The manufacturer’s 
instructions state that the energy required to produce tendi-
nous injury is 0.540 J. Therefore, three 0.05 kg metal blocks 
(0.150 kg in total) were left to fall together, sliding along a 
12 cm vertical ruler. This impact generated kinetic energy of 
0.540 J, meeting the manufacturer’s specifications.
Treatment
Prior to iontophoresis, skin impedance was determined 
by trichotomy in the injury site. Using a previously 
calibrated iontophoresis device (Endophasys D; KLD 
Equipment, São Paulo, Brazil), animals were submitted to 
daily 12-minute iontophoresis sessions of direct electro-
therapy for 5 days. According to Agne,20 the transmitted 
electrical current is measured by multiplying the active 
electrode area by the constant 0.15. The electrodes used 
measured 1.5 cm² and therefore the electrical current 
applied was 0.3 mA.   Iontophoresis started immediately 
after injury challenge and sessions were always con-
ducted at the same time. The negative electrode was 
loaded with diclofenac diethylammonium gel (11.6 mg/g) 
and GNP gel as the transmission medium and placed on 
the injury site, while the positive electrode was loaded 
with basic conductive gel and placed on the gastrocnemius 
myotendinous joint.
sample preparation
Animals were sacrificed by decapitation 2 hours after the 
last session. The Achilles tendons were surgically removed 
and immediately homogenized in an extraction buffer 
(1% Triton-X 100, 100 mM Tris, pH 7.4, containing 100 mM 
sodium pyrophosphate, 100 mM sodium fluoride, 10 mM 
ethylenediaminetetraacetic acid, 10 mM sodium vanadate, 
2 mM phenylmethanesulfonylfluoride, and 0.1 mg/mL 
aprotinin) at 4°C with a Polytron® PT-MR 2100 (Kine-
matica AG, Lucerne, Switzerland) and stored at −70°C for 
analysis. All chemicals were purchased from Sigma Aldrich   
(St Louis, MO).
A preliminary assay defined the suitable number of ten-
dons for molecular analysis, revealing that a pool of three 
tendons was required to form a representative sample. The 
initial population was formed by 60 rats, and since three International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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iontophoresis protocols were tested, each experimental group 
used 15 rats (plus one external control of identical number 
of animals). Therefore, the net number of tendons for each 
molecular analysis sample was five. Aliquots of samples thus 
prepared were retrieved, centrifuged at 1000 g for 10 minutes 
at 4°C, and kept at −70°C until use. The contralateral tendon 
of one rat, subjected to the same treatment techniques but not 
challenged with injury, was used as internal control.
Protein analysis by immunoblotting
The extracts obtained, as described above, were centrifuged 
at 11,000 rpm and 4°C in an Eppendorf Centrifuge 5804R 
(Eppendorf AG, Hamburg, Germany) for 40 minutes to 
remove insoluble material, and the supernatants of this 
  tissue were used for protein quantification, according 
to the Bradford method.21 Proteins were denaturated by 
boiling in Laemmli sample buffer22 containing 100 mM 
  dithiothreitol, run on 15% sodium dodecyl sulfate poly-
acrylamide gel   electrophoresis, transferred to nitrocellulose 
  membranes. Membranes were blocked, probed, and 
  developed. Antibodies used for immunoblotting were 
anti-TNF-α and anti-IL-1β (Santa Cruz Biotechnology, 
Santa Cruz, CA). Chemiluminescent detection was performed 
with horseradish peroxidase-conjugate secondary antibodies 
(Thermo Scientific, Rockford, IL). Autoradiographs of 
membranes were taken for visualization of protein bands. 
The results of blots are presented as direct comparisons of 
bands in “photographic films” and quantified by densitometry 
using the Scion Image software (v 4.0.3.2; Scion Corpora-
tion, Frederick, MD).
statistical analysis
Data are expressed as mean and standard error of the mean. 
The data were analyzed using SPSS statistical software 
(v 17.0; IBM Corp, Armonk, NY) based on a one-way 
analysis of variance (ANOVA) followed by a post-hoc Tukey 
test to compare the study groups, with significance level of 
95% (P  0.05).
Results
Results presented are part of the findings of a more compre-
hensive study that analyzes the two inflammatory cytokines 
in the inflammatory stage of the injury (IL-1β and TNF-α). 
In these results, the expression of these cytokines was 
analyzed in iontophoresis as a treatment approach (in the 
present paper), and the therapeutic pulsed ultrasound (TPU) 
associated with diclofenac and GNPs. The results of  TPU 
are the subject of another publication.
characterization of gNPs
The electronic spectrum of the GNP solution presented one 
plasmon band at 520 nm, which agrees with a value previ-
ously described.23 Field emission gun microscopy analysis 
revealed that GNPs presented a spheroid shape with mean 
diameter of 35 mm. The newly prepared nanoparticle solution 
was centrifuged and the supernatant was collected and added 
to a gel base commonly used in physiotherapy (1:1 w/w).
IL-1β
Figure 1 shows the levels of IL-1β determined by West-
ern blotting. The external control group (injury chal-
lenged animals with no treatment) showed high IL-β 
expression (3591 ± 213). Yet, a significant reduction in 
IL-1β was observed in the iontophoresis + diclofenac and 
iontophoresis + GNPs groups, in comparison with the 
external control. However, the group treated with ionto-
phoresis + diclofenac + GNPs exhibited the lowest IL-1β 
expression (1732 ± 239; P  0.05), with statistical signifi-
cance in comparison with the iontophoresis + diclofenac or 
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Figure 1 effect of iontophoresis with diclofenac diethylammonium, gold nanoparticle 
gel, and association thereof on interleukin 1 beta (IL-1β) expression after a 5-day 
treatment period.
Notes:  Data  expressed  as  mean  ±  standard  deviation  for  15  animals  of  each 
treatment  group.  *P    0.05  in  comparison  with  the  control  of  the  group  not 
exposed to injury;  #P  0.05 in comparison with the group exposed to injury; 
$P  0.05 with comparison to the groups treated with iontophoresis + diclofenac 
and iontophoresis + gNPs. control, external control tendon, no treatment; injury, 
injured tendon without treatment.
Abbreviations: c, control; L, lesion; I + c/c, iontophoresis + diclofenac/internal 
control  tendon;  I  +  c/L,  iontophoresis  +  diclofenac/injured  tendon;  I  +  N/c, 
iontophoresis  +  gNPs/control  tendon;  I  +  N/L,  iontophoresis  +  gNPs/injured 
tendon; I + N + c/c, iontophoresis + gNPs + diclofenac/internal control tendon; 
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GNPs applied individually, and even similar to the internal 
control value.
TNF-α
TNF-α levels were analyzed by Western blotting. Similarly 
to IL-1β, TNF-α levels were high in the external control 
group (6126 ± 527). Statistically significant decrease in 
TNF-α expression was observed only in the iontophore-
sis + diclofenac + GNPs group, in the treatment conditions 
described (3221 ± 36; P  0.05; Figure 2).
Discussion
The existence of an inflammatory stage in the injury was 
observed, with increased inflammatory cytokine expression 
in all groups challenged with injury. In the present study, 
diclofenac diethylammonium, GNPs, and an association of 
both were administered using direct current (iontophoresis) 
in Wistar rats challenged with a tendinopathy model. The 
expression of proinflammatory cytokines IL-1β and TNF-α. 
The results obtained revealed a significant decrease in IL-1β 
expression in the three treatment groups, when compared 
with the external control group (injury-challenged rats 
without treatment). However, the lowest IL-1β expression 
was observed in the iontophoresis + diclofenac + GNPs 
group, with statistically significant difference against the 
other treatment groups. Moreover, for the same combined 
treatment group, no statistically significant difference 
was observed in IL-1β expression in comparison with 
the internal control (unchallenged contralateral tendon). 
Based on the general principle of electrical transmission – 
that is, same-charge ions repel one another while differently 
charged ions are attracted to one another – a negatively 
charged drug has to be loaded onto the negative electrode, 
so that it migrates to the positive electrode. This electrical 
repulsive force conducts the drug inside the organism, toward 
the opposite electrode distally placed.23
In the present study, diclofenac diethylammonium, 
GNPs, and an association of both were administered using 
direct current (iontophoresis) in Wistar rats challenged with 
a tendinopathy model: the expression of proinflammatory 
cytokines IL-1β and TNF-α. The results obtained revealed 
a significant decrease in IL-1β expression in the three treat-
ment groups, when compared with the external control group 
(injury-challenged rats without treatment). However, the 
lowest IL-1β expression was observed in the iontophoresis + 
diclofenac + GNPs group, with statistically significant dif-
ference against the other treatment groups. Moreover, for the 
same combined treatment group, no statistically significant 
difference was observed in IL-1β expression in comparison 
with the internal control (unchallenged   contralateral   tendon). 
In contrast to IL-1β expression, for which significant 
decreases were observed in all treatment groups, a significant 
drop in TNF-α expression was observed only in the ionto-
phoresis + diclofenac + GNPs treatment group.
It appears that this is the first study to investigate the 
use of iontophoresis associated with drugs and metallic 
nanoparticles to treat tendinopathy, and to evaluate the 
expression of these proinflammatory cytokines in this kind 
of intervention. Chwalibog et al24 assessed the morphologi-
cal characteristics of gold, silver, platinum, and diamond 
nanoparticles in terms of an interaction with bacteria and 
fungi. The authors reported negative zeta potential values for 
platinum (−9.6 mV), silver (−9.2 mV), and gold (−1.9 mV), 
explaining how these nanoparticles were harmful to the 
bacteria and fungi used. In the present study, the positive 
electrode was placed on the gastrocnemius myotendinous 
joint, while the negative electrode was placed on the injury 
site. The gel containing GNPs and the gel associating 
GNPs + diclofenac diethylammonium were loaded only on 
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Figure 2 effect of iontophoresis with diclofenac diethylammonium, gold nanoparticle 
gel, and association thereof on tumor necrosis factor alpha (TNF-α) expression 
after a 5-day treatment period.
Notes: Data expressed as mean ± standard deviation for 15 animals of each treatment 
group. *P  0.05 in comparison to the control of the group not exposed to injury; 
$P  0.05 in comparison to the groups treated with iontophoresis + diclofenac and 
iontophoresis  +  gNPs.  control,  external  control  tendon,  no  treatment;  injury, 
injured tendon without treatment.
Abbreviations: I + c/c, iontophoresis + diclofenac/internal control tendon; I + c/L, 
iontophoresis + diclofenac/injured tendon; I + N/c, iontophoresis + gNPs/control 
tendon; I + N/L, iontophoresis + gNPs/injured tendon; I + N + c/c, iontophoresis 
+ gNPs + diclofenac/internal control tendon; I + N + c/L, iontophoresis + gNPs +   
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the negative electrode, while on the positive electrode gel 
base was used, which was also  both electrodes as a trans-
mission medium. Since GNPs have negative zeta potential, 
they migrated from the gastrocnemius (negative pole) to the 
Achilles tendon (positive pole).
Similar results were obtained in several previous studies, 
which reported appreciable levels of other drugs in deeper 
tissue layers after iontophoretic transdermal application. 
Glass et al25 demonstrated the penetration of dexamethasone 
in tissues below an injury site in monkeys. Other studies have 
reported the depth lidocaine reaches in human subcutaneous 
tissue via iontophoresis, demonstrating that the drug may 
reach 1.25 cm below the application site.26,27 Kigsawa 
et al28 used iontophoresis to transdermally transport CpG 
oligonucleotide in melanoma therapy. The authors observed 
the induction of a strong antitumor activity in a simple, 
noninvasive, and efficient approach to treat cancer.
Sonanave et al29 evaluated the role of GNP particle size 
(15, 102, and 198 nm) in penetration in rat skin. GNPs showed 
negative zeta potential and, the smaller the particle size, the 
higher the penetration rates in tissues. The authors concluded 
that GNPs are an attractive alternative for the transdermal 
transport of drugs, especially when smaller particles are used. 
In the present study, spherical GNPs measuring on average 
30 nm were used. It is possible to hypothesize that the binding 
of this kind of nanoparticle to diclofenac diethylammonium 
afforded a more effective transport to the injury site. The ther-
apeutic procedure using iontophoresis + diclofenac + GNPs 
reduced IL-1β to levels equivalent to those measured in the 
control group. This apparent synergism may be explained 
in the light of the interaction between GNPs and the groups 
−COOH and −NH in diclofenac, which are transported 
through the tissue to the injury site by iontophoresis, accord-
ing to Nobuo30 and Selvakannan et al.14
Pedersen et al16 evaluated the effects of GNPs on TNF-α 
on a focal brain injury. The results obtained demonstrate a 
significant drop in brain TNF-α in the GNPs group. Tsai 
et al15 induced rheumatoid arthritis in an animal model 
and assessed inflammatory responses after intra-articular 
GNP administration. In that study, the authors observed 
significantly reduced intra-articular levels of IL-1β and 
TNF-α in treated rats. This was confirmed in the results 
of the present study, when GNPs, apart from their ability 
to reduce IL-1β and TNF-α expression in treated groups, 
were also efficient in the nanotransportation of drugs to the 
active inflammatory sites, as also reported by Ghosh et al.13 
Further studies are being conducted by the authors of the 
current paper to assess oxidative stress, vascular endothelial 
growth factor, and metalloproteinase levels. The decrease in 
expression of inflammatory cytokines in tendinitis observed 
with the association diclofenac + GNPs and iontophoresis is 
an important factor in the control of the subsequent stages of 
tendinopathy. The inflammatory response should be strong 
enough to control the initial injury, which decreases the 
chances of higher secondary fibroblast proliferation and the 
resulting tendon degeneration. Iontophoresis associated with 
anti-inflammatory drugs has been used in the treatment of the 
acute stage of these injuries. The possibility to successfully 
treat the initial stage of tendinitis leads the authors to believe 
that it is possible to decrease the occurrence of tendinous 
rupture caused by tendon degeneration. These studies may 
shed new light on the mechanisms behind the interaction of 
iontophoresis and diclofenac diethylammonium and GNPs 
in tendinous injury scenarios.
Conclusion
The authors believe the results of the present paper to be 
the first to demonstrate the effect of GNPs associated to 
diclofenac diethylammonium transdermally administered 
using direct electric current in an animal tendinopathy 
model. GNPs exerted anti-inflammatory and synergistic 
action: enabling the transport the drug used and enhanc-
ing the therapeutic role of iontophoresis in the control of 
inflammatory cytokines IL-1β and TNF-α in a tendinopathy 
animal model.
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